Array BioPharma
 | This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. (July 2020) |
| Company type | Subsidiary of Pfizer |
|---|---|
| Industry | Oncology Medication |
| Founded | 1998 |
| Founder | Drs. Tony Piscopio, Kevin Koch, David Snitman, and K.C. Nicolaou |
| Headquarters | , |
| Revenue | $173.8 million (2018) |
| Parent | Pfizer |
| Website | www |
Array BioPharma is a U.S.-based, clinical stage, pharmaceutical company that focuses on oncology medication. The company is a subsidiary of Pfizer.
History
In 1998, the company was founded by Drs. Tony Piscopio, Kevin Koch, David Snitman, and K.C. Nicolaou.[1]
In November 2000, the company became a public company via an initial public offering.[2]
In July 2013, the company partnered with Loxo Oncology to develop cancer drugs.[3]
In November 2015, the company signed a partnership with Laboratoires Pierre Fabre.[4]
In 2016, the company collaborated with Laboratoires Pierre Fabre for a phase three trial for a treatment of BRAF-mutant metastatic colorectal cancer.[5]
In May 2017, the company partnered with Ono Pharmaceutical to test the combination of binimetinib and encorafenib while retaining commercialization rights in the U.S. and other markets.[6]
In 2017, the company spun out one of its programs into a subsidiary called Yarra; the asset was a molecule called ARRY-797 that was in a Phase II trial for cardiomyopathy.[7]
In March 2018, Array sued AstraZeneca for breach of contract, saying that AstraZeneca owed it a 12% royalty on a portion of the $1.6 billion upfront payment that Merck had paid to AstraZeneca in a deal for selumetinib, which Array said it had licensed to AstraZeneca in 2003.[8]
In June 2018, the combination of BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) was approved by the Food and Drug Administration for the treatment of people with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma.[9]
On September 20, 2018, the European Commission approved BRAFTOVI® in combination with MEKTOVI® for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation, as detected by a validated test.[10]
In July 2019, Pfizer acquired the company[11] for approximately $11 billion.[12][13]
References
- ^ "Co-Founder Of Array BioPharma, Inc. To Lead New Korean Out-Sourcing Chemistry Company". BioSpace. Retrieved 2020-07-28.
- ^ "Array IPO up 17%". CNN. November 17, 2000.
- ^ "Loxo Oncology And Array BioPharma Announce License And Collaboration Agreement" (Press release). PR Newswire. July 10, 2013.
- ^ "Innovation and Partnerships". Laboratoires Pierre Fabre.
- ^ Hughes, Emily (June 6, 2016). "Merck, Pierre Fabre and Array BioPharma collaborate for cancer drug clinical trial". EPM Magazine.
- ^ "Array BioPharma And Ono Pharmaceutical Co., Ltd. Announce A License, Development And Commercialization Partnership For Two Novel Oncology Compounds, Binimetinib And Encorafenib" (Press release). PR Newswire. May 31, 2017.
- ^ Castle, Shay (December 26, 2017). "Boulder's Array BioPharma spins out subsidiary to develop rare-disease drugs". The Denver Post.
- ^ Vogt, RJ (March 19, 2018). "AstraZeneca Owes $192M For Cancer Drug Rights, Rival Says". Law360.
- ^ "FDA approves encorafenib and binimetinib in combination for unresectable or metastatic melanoma with BRAF mutations" (Press release). Food and Drug Administration. June 27, 2018.
- ^ "Pierre Fabre Receives EU Approval for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in Adult Patients with Advanced BRAF-Mutant Melanoma" (Press release). Business Wire. September 20, 2018.
- ^ "PFIZER COMPLETES ACQUISITION OF ARRAY BIOPHARMA" (Press release). Pfizer. July 30, 2019.
- ^ "Array played with Pfizer's eagerness to land a deal on time—and got itself a better offer". FiercePharma. Retrieved 2020-07-29.
- ^ "Pfizer acquires Array BioPharma, valued at $11.4 billion". Rappler. Retrieved 2020-07-29.
- 1998 establishments in Colorado
- 2000 initial public offerings
- 2019 mergers and acquisitions
- Pharmaceutical companies established in 1998
- Biotechnology companies established in 1998
- Pharmaceutical companies of the United States
- Companies formerly listed on NASDAQ
- Biotechnology companies of the United States
- Health care companies based in Colorado
- Companies based in Boulder, Colorado
- Pfizer
- Biopharmaceutical companies